Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials.

Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials.

BACKGROUND:The comparison between long acting insulin analogues (LAIA) and human insulin (NPH) has been investigated for decades, with many randomized controlled trials (RCTs) and systematic reviews giving mixed results. This overlapping and contradictory evidence has increased uncertainty on covera...

Full description

Bibliographic Details
Main Authors:	Fernanda O Laranjeira, Keitty R C de Andrade, Ana C M G Figueiredo, Everton N Silva, Mauricio G Pereira
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2018-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5896894?pdf=render

Similar Items

Budget Impact of Long-Acting Insulin Analogues: The Case in Brazil.
by: Fernanda O Laranjeira, et al.
Published: (2016-01-01)

Insulin degludec is a new ultra-long-acting insulin analogue
by: Ivan Ivanovich Dedov, et al.
Published: (2014-07-01)

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine
by: E Warren, et al.
Published: (2004-11-01)

Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10.
by: Bo F Hansen, et al.
Published: (2012-01-01)

Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
by: Beng Leong Lim, et al.
Published: (2023-02-01)

Insulin degludec: overview of a novel ultra long-acting basal insulin.
by: Gough, S, et al.
Published: (2013)

Insulin degludec: Overview of a novel ultra long-acting basal insulin
by: Gough, S, et al.
Published: (2013)

A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes
by: Chun-Ting Yang, et al.
Published: (2021-02-01)

Long-acting insulin analogue in the treatment of type 2 diabetes mellitus: emphasis on proven efficacy and safety
by: E. V. Biryukova, et al.
Published: (2021-09-01)

Prescription patterns of long-acting somatostatin analogues
by: Jorge Enrique Machado-Alba, et al.
Published: (2017-03-01)

Efficacy, Pharmacokinetics, Biodistribution and Excretion of a Novel Acylated Long-Acting Insulin Analogue INS061 in Rats
by: Pan K, et al.
Published: (2021-08-01)

Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis
by: Karla F. S. Melo, et al.
Published: (2019-01-01)

Corrigendum: Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogues
by: Kevin C. J. Yuen, et al.
Published: (2021-06-01)

Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus
by: Eun Yeong Choe, et al.
Published: (2012-06-01)

NEW DRUG IN THE EVOLUTION OF LONG-ACTING INSULINS
by: I. V. Kononenko, et al.
Published: (2018-01-01)

Current european regulatory perspectives on insulin analogues
by: Enzmann Harald G, et al.
Published: (2011-07-01)

A review of human and analogue insulin trials.
by: Gough, S
Published: (2007)

THE USE OF ULTRA-LONG-ACTING INSULIN ANALOGUE DEGLUDEC IN TYPE 1 DIABETES MELLITUS IN CLINICAL PRACTICE: THE INFLUENCE ON QUALITY OF LIFE AND SATISFACTION WITH TREATMENT
by: M. F. Kalashnikova, et al.
Published: (2016-12-01)

Effects of Ultra-Long-Acting Insulin Compared to Long-Acting Insulin on Diabetic Ketoacidosis Incidence in Type 1 Diabetes Mellitus Patients
by: Alsofiani WA, et al.
Published: (2022-03-01)

Engineering of insulin receptor isoform-selective insulin analogues.
by: Tine Glendorf, et al.
Published: (2011-01-01)

A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300
by: Oppel B.W. Greeff, et al.
Published: (2018-08-01)

Insulin analogues versus human insulin in type 1 diabetes: direct and indirect meta-analyses of efficacy and safety
by: Andréia Cristina Conegero Sanches, et al.
Published: (2013-09-01)

The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future
by: Brian Godman, et al.
Published: (2021-06-01)

Efficacy and safety of ultra-long-acting insulin degludec
by: Ammar Wakil, et al.
Published: (2012-04-01)

Comparative efficacy and complications of long-acting and intermediate-acting insulin regimens for adults with type 1 diabetes: an individual patient data network meta-analysis
by: Dimitris Mavridis, et al.
Published: (2022-11-01)

Assignment of polymorphic species of insulin analogues in ion mobility mass spectroscopy
by: Maely P. Fávero-Retto, et al.
Published: (2017-02-01)

Análogos de insulina Insulin analogues
by: Manuel E. Licea Puig
Published: (2006-12-01)

Safety and Efficacy of Modern Insulin Analogues
by: Hye Jin Yoo, et al.
Published: (2013-06-01)

Characterisation of insulin analogues therapeutically available to patients.
by: Gary G Adams, et al.
Published: (2018-01-01)

Knowledge translation in the reality of Brazilian public health
by: Keitty Regina Cordeiro de Andrade, et al.
Published: (2020-07-01)

A new long-acting insulin (HOE901) demonstrates less nocturnal hypoglycaemia when compared with protamine insulin in a clinical trial.
by: Matthews, DR, et al.
Published: (1998)

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014-12-01)

Prevalence of Frailty in Latin America and the Caribbean: A Systematic Review and Meta-Analysis.
by: Fabiana Araújo Figueiredo Da Mata, et al.
Published: (2016-01-01)

Cell Adhesive Character of Phenylboronic Acid-Modified Insulin and Its Potential as Long-Acting Insulin
by: Yui Ohno, et al.
Published: (2019-08-01)

Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes
by: Marina Vladimirovna Shestakova, et al.
Published: (2015-12-01)

Insulin analogues and cancer: a note of caution
by: Joseph A.M.J.L. eJanssen, et al.
Published: (2014-05-01)

Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?
by: Anna Sowa-Staszczak, et al.
Published: (2021-11-01)

Does Glyphosate Acting as a Glycine Analogue Contribute To ALS?
by: Seneff, Stephanie, et al.
Published: (2017)

Long-acting muscarinic antagonists vs. long-acting β 2 agonists in COPD exacerbations: a systematic review and meta-analysis
by: Israel Silva Maia, et al.

Modeling Between-Subject Variability in Subcutaneous Absorption of a Fast-Acting Insulin Analogue by a Nonlinear Mixed Effects Approach
by: Edoardo Faggionato, et al.
Published: (2021-04-01)